25 XP   0   0   10

Concord Drugs Ltd
Buy, Hold or Sell?

Let's analyse Concord Drugs Ltd together

PenkeI guess you are interested in Concord Drugs Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Concord Drugs Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Concord Drugs Ltd

I send you an email if I find something interesting about Concord Drugs Ltd.

Quick analysis of Concord Drugs Ltd (30 sec.)










What can you expect buying and holding a share of Concord Drugs Ltd? (30 sec.)

How much money do you get?

How much money do you get?
INR0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
INR34.03
Expected worth in 1 year
INR40.43
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
INR6.40
Return On Investment
17.8%

For what price can you sell your share?

Current Price per Share
INR35.90
Expected price per share
INR32.85 - INR40.95
How sure are you?
50%

1. Valuation of Concord Drugs Ltd (5 min.)




Live pricePrice per Share (EOD)

INR35.90

Intrinsic Value Per Share

INR-20.66 - INR-24.36

Total Value Per Share

INR13.37 - INR9.67

2. Growth of Concord Drugs Ltd (5 min.)




Is Concord Drugs Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$3.8m$3.4m$401.2k10.5%

How much money is Concord Drugs Ltd making?

Current yearPrevious yearGrowGrow %
Making money$118.2k$191.3k-$73k-61.8%
Net Profit Margin1.9%2.7%--

How much money comes from the company's main activities?

3. Financial Health of Concord Drugs Ltd (5 min.)




What can you expect buying and holding a share of Concord Drugs Ltd? (5 min.)

Welcome investor! Concord Drugs Ltd's management wants to use your money to grow the business. In return you get a share of Concord Drugs Ltd.

What can you expect buying and holding a share of Concord Drugs Ltd?

First you should know what it really means to hold a share of Concord Drugs Ltd. And how you can make/lose money.

Speculation

The Price per Share of Concord Drugs Ltd is INR35.90. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Concord Drugs Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Concord Drugs Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR34.03. Based on the TTM, the Book Value Change Per Share is INR1.60 per quarter. Based on the YOY, the Book Value Change Per Share is INR1.82 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Concord Drugs Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.010.0%0.010.0%0.020.1%0.020.1%0.020.1%
Usd Book Value Change Per Share0.020.1%0.020.1%0.020.1%0.080.2%0.080.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.020.1%0.020.1%0.020.1%0.080.2%0.080.2%
Usd Price Per Share0.33-0.33-0.35-0.29-0.29-
Price to Earnings Ratio25.95-25.95-15.90-25.03-25.03-
Price-to-Total Gains Ratio17.17-17.17-15.90-7.30-7.30-
Price to Book Ratio0.81-0.81-0.89-0.77-0.77-
Price-to-Total Gains Ratio17.17-17.17-15.90-7.30-7.30-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.4308
Number of shares2321
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.020.08
Usd Total Gains Per Share0.020.08
Gains per Quarter (2321 shares)44.53189.58
Gains per Year (2321 shares)178.13758.34
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101781680758748
20356346015171506
30534524022752264
40713702030333022
50891880037923780
6010691058045504538
7012471236053085296
8014251414060676054
9016031592068256812
10017811770075837570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%4.01.00.080.0%4.01.00.080.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.05.00.0%0.00.05.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%4.01.00.080.0%4.01.00.080.0%

Fundamentals of Concord Drugs Ltd

About Concord Drugs Ltd

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Concord Drugs Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Concord Drugs Ltd earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • A Net Profit Margin of 1.9% means that ₹0.02 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Concord Drugs Ltd:

  • The MRQ is 1.9%. The company is making a profit. +1
  • The TTM is 1.9%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ1.9%TTM1.9%0.0%
TTM1.9%YOY2.7%-0.8%
TTM1.9%5Y2.5%-0.6%
5Y2.5%10Y2.5%0.0%
1.1.2. Return on Assets

Shows how efficient Concord Drugs Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • 1.7% Return on Assets means that Concord Drugs Ltd generated ₹0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Concord Drugs Ltd:

  • The MRQ is 1.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.7%TTM1.7%0.0%
TTM1.7%YOY2.8%-1.1%
TTM1.7%5Y2.4%-0.7%
5Y2.4%10Y2.4%0.0%
1.1.3. Return on Equity

Shows how efficient Concord Drugs Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • 3.1% Return on Equity means Concord Drugs Ltd generated ₹0.03 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Concord Drugs Ltd:

  • The MRQ is 3.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.1%TTM3.1%0.0%
TTM3.1%YOY5.6%-2.5%
TTM3.1%5Y4.8%-1.7%
5Y4.8%10Y4.8%0.0%

1.2. Operating Efficiency of Concord Drugs Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Concord Drugs Ltd is operating .

  • Measures how much profit Concord Drugs Ltd makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Concord Drugs Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y1.6%-1.6%
5Y1.6%10Y1.6%0.0%
1.2.2. Operating Ratio

Measures how efficient Concord Drugs Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 1.73 means that the operating costs are ₹1.73 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Concord Drugs Ltd:

  • The MRQ is 1.729. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.729. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.729TTM1.7290.000
TTM1.729YOY1.559+0.170
TTM1.7295Y1.731-0.002
5Y1.73110Y1.7310.000

1.3. Liquidity of Concord Drugs Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Concord Drugs Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 2.01 means the company has ₹2.01 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Concord Drugs Ltd:

  • The MRQ is 2.010. The company is able to pay all its short-term debts. +1
  • The TTM is 2.010. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.010TTM2.0100.000
TTM2.010YOY1.772+0.239
TTM2.0105Y1.743+0.267
5Y1.74310Y1.7430.000
1.3.2. Quick Ratio

Measures if Concord Drugs Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • A Quick Ratio of 0.73 means the company can pay off ₹0.73 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Concord Drugs Ltd:

  • The MRQ is 0.732. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.732. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.732TTM0.7320.000
TTM0.732YOY0.968-0.235
TTM0.7325Y0.933-0.200
5Y0.93310Y0.9330.000

1.4. Solvency of Concord Drugs Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Concord Drugs Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Concord Drugs Ltd to industry mean.
  • A Debt to Asset Ratio of 0.46 means that Concord Drugs Ltd assets are financed with 45.6% credit (debt) and the remaining percentage (100% - 45.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Concord Drugs Ltd:

  • The MRQ is 0.456. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.456. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.456TTM0.4560.000
TTM0.456YOY0.498-0.042
TTM0.4565Y0.546-0.091
5Y0.54610Y0.5460.000
1.4.2. Debt to Equity Ratio

Measures if Concord Drugs Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • A Debt to Equity ratio of 83.7% means that company has ₹0.84 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Concord Drugs Ltd:

  • The MRQ is 0.837. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.837. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.837TTM0.8370.000
TTM0.837YOY0.990-0.154
TTM0.8375Y1.347-0.510
5Y1.34710Y1.3470.000

2. Market Valuation of Concord Drugs Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Concord Drugs Ltd generates.

  • Above 15 is considered overpriced but always compare Concord Drugs Ltd to the  industry mean.
  • A PE ratio of 25.95 means the investor is paying ₹25.95 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Concord Drugs Ltd:

  • The EOD is 33.935. Based on the earnings, the company is overpriced. -1
  • The MRQ is 25.947. Based on the earnings, the company is overpriced. -1
  • The TTM is 25.947. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD33.935MRQ25.947+7.987
MRQ25.947TTM25.9470.000
TTM25.947YOY15.905+10.042
TTM25.9475Y25.029+0.918
5Y25.02910Y25.0290.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Concord Drugs Ltd:

  • The EOD is 41.471. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 31.710. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 31.710. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD41.471MRQ31.710+9.761
MRQ31.710TTM31.7100.000
TTM31.710YOY-15.076+46.786
TTM31.7105Y7.572+24.138
5Y7.57210Y7.5720.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Concord Drugs Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 0.81 means the investor is paying ₹0.81 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Concord Drugs Ltd:

  • The EOD is 1.055. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.807. Based on the equity, the company is cheap. +2
  • The TTM is 0.807. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.055MRQ0.807+0.248
MRQ0.807TTM0.8070.000
TTM0.807YOY0.894-0.088
TTM0.8075Y0.770+0.036
5Y0.77010Y0.7700.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Concord Drugs Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.5991.5990%1.823-12%6.807-77%6.807-77%
Book Value Per Share--34.03434.0340%32.435+5%30.679+11%30.679+11%
Current Ratio--2.0102.0100%1.772+13%1.743+15%1.743+15%
Debt To Asset Ratio--0.4560.4560%0.498-8%0.546-17%0.546-17%
Debt To Equity Ratio--0.8370.8370%0.990-16%1.347-38%1.347-38%
Dividend Per Share----0%-0%-0%-0%
Eps--1.0581.0580%1.823-42%1.506-30%1.506-30%
Free Cash Flow Per Share--0.8660.8660%-1.924+322%-0.536+162%-0.536+162%
Free Cash Flow To Equity Per Share--0.8660.8660%-1.924+322%-0.722+183%-0.722+183%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---24.364--------
Intrinsic Value_10Y_min---20.660--------
Intrinsic Value_1Y_max---1.906--------
Intrinsic Value_1Y_min---1.852--------
Intrinsic Value_3Y_max---6.135--------
Intrinsic Value_3Y_min---5.786--------
Intrinsic Value_5Y_max---10.855--------
Intrinsic Value_5Y_min---9.934--------
Market Cap--255709651.500255709651.5000%253568750.000+1%208663460.300+23%208663460.300+23%
Net Profit Margin--0.0190.0190%0.027-30%0.025-24%0.025-24%
Operating Margin----0%-0%0.016-100%0.016-100%
Operating Ratio--1.7291.7290%1.559+11%1.7310%1.7310%
Pb Ratio1.055+24%0.8070.8070%0.894-10%0.770+5%0.770+5%
Pe Ratio33.935+24%25.94725.9470%15.905+63%25.029+4%25.029+4%
Price Per Share35.900+24%27.45027.4500%29.000-5%23.930+15%23.930+15%
Price To Free Cash Flow Ratio41.471+24%31.71031.7100%-15.076+148%7.572+319%7.572+319%
Price To Total Gains Ratio22.454+24%17.16917.1690%15.904+8%7.296+135%7.296+135%
Quick Ratio--0.7320.7320%0.968-24%0.933-21%0.933-21%
Return On Assets--0.0170.0170%0.028-40%0.024-30%0.024-30%
Return On Equity--0.0310.0310%0.056-45%0.048-36%0.048-36%
Total Gains Per Share--1.5991.5990%1.823-12%6.807-77%6.807-77%
Usd Book Value--3804528.0003804528.0000%3403272.000+12%3203333.839+19%3203333.839+19%
Usd Book Value Change Per Share--0.0190.0190%0.022-12%0.082-77%0.082-77%
Usd Book Value Per Share--0.4080.4080%0.389+5%0.368+11%0.368+11%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0130.0130%0.022-42%0.018-30%0.018-30%
Usd Free Cash Flow--96768.00096768.0000%-201828.000+309%-57316.109+159%-57316.109+159%
Usd Free Cash Flow Per Share--0.0100.0100%-0.023+322%-0.006+162%-0.006+162%
Usd Free Cash Flow To Equity Per Share--0.0100.0100%-0.023+322%-0.009+183%-0.009+183%
Usd Market Cap--3068515.8183068515.8180%3042825.000+1%2503961.524+23%2503961.524+23%
Usd Price Per Share0.431+24%0.3290.3290%0.348-5%0.287+15%0.287+15%
Usd Profit--118260.000118260.0000%191316.000-38%158322.641-25%158322.641-25%
Usd Revenue--6249672.0006249672.0000%7074780.000-12%6283445.345-1%6283445.345-1%
Usd Total Gains Per Share--0.0190.0190%0.022-12%0.082-77%0.082-77%
 EOD+2 -4MRQTTM+0 -0YOY+16 -165Y+16 -1710Y+16 -17

3.2. Fundamental Score

Let's check the fundamental score of Concord Drugs Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1533.935
Price to Book Ratio (EOD)Between0-11.055
Net Profit Margin (MRQ)Greater than00.019
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.732
Current Ratio (MRQ)Greater than12.010
Debt to Asset Ratio (MRQ)Less than10.456
Debt to Equity Ratio (MRQ)Less than10.837
Return on Equity (MRQ)Greater than0.150.031
Return on Assets (MRQ)Greater than0.050.017
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Concord Drugs Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.742
Ma 20Greater thanMa 5037.500
Ma 50Greater thanMa 10040.822
Ma 100Greater thanMa 20040.797
OpenGreater thanClose34.000
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets582,310
Total Liabilities265,266
Total Stockholder Equity317,044
 As reported
Total Liabilities 265,266
Total Stockholder Equity+ 317,044
Total Assets = 582,310

Assets

Total Assets582,310
Total Current Assets434,564
Long-term Assets147,745
Total Current Assets
Cash And Cash Equivalents 784
Short-term Investments 210
Net Receivables 158,101
Inventory 200,647
Other Current Assets 474
Total Current Assets  (as reported)434,564
Total Current Assets  (calculated)360,216
+/- 74,348
Long-term Assets
Property Plant Equipment 131,374
Long-term Assets Other 667
Long-term Assets  (as reported)147,745
Long-term Assets  (calculated)132,041
+/- 15,704

Liabilities & Shareholders' Equity

Total Current Liabilities216,148
Long-term Liabilities49,118
Total Stockholder Equity317,044
Total Current Liabilities
Short Long Term Debt 150,534
Accounts payable 52,722
Other Current Liabilities 951
Total Current Liabilities  (as reported)216,148
Total Current Liabilities  (calculated)204,207
+/- 11,941
Long-term Liabilities
Long term Debt 19,113
Long-term Liabilities Other -1
Long-term Liabilities  (as reported)49,118
Long-term Liabilities  (calculated)19,112
+/- 30,006
Total Stockholder Equity
Retained Earnings 143,991
Total Stockholder Equity (as reported)317,044
Total Stockholder Equity (calculated)143,991
+/- 173,053
Other
Capital Stock93,155
Common Stock Shares Outstanding 9,315
Net Debt 168,863
Net Invested Capital 486,691
Net Working Capital 218,416
Property Plant and Equipment Gross 378,920



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
> Total Assets 
0
0
827,685
580,155
498,827
564,451
582,310
582,310564,451498,827580,155827,68500
   > Total Current Assets 
602,453
920,191
697,377
455,640
360,254
418,907
434,564
434,564418,907360,254455,640697,377920,191602,453
       Cash And Cash Equivalents 
0
0
1,589
121
355
444
784
7844443551211,58900
       Short-term Investments 
0
0
259
259
210
210
210
21021021025925900
       Net Receivables 
460,508
711,723
484,347
254,460
207,280
228,585
158,101
158,101228,585207,280254,460484,347711,723460,508
       Inventory 
110,270
186,194
186,415
164,313
118,718
174,899
200,647
200,647174,899118,718164,313186,415186,194110,270
       Other Current Assets 
29,331
21,717
24,767
36,488
6,352
2,673
474
4742,6736,35236,48824,76721,71729,331
   > Long-term Assets 
0
0
130,308
124,514
138,574
145,545
147,745
147,745145,545138,574124,514130,30800
       Property Plant Equipment 
128,492
127,238
113,521
107,366
131,915
137,831
131,374
131,374137,831131,915107,366113,521127,238128,492
       Long-term Assets Other 
0
0
-7,562
-3
-1
1,000
667
6671,000-1-3-7,56200
> Total Liabilities 
0
0
596,121
345,309
231,165
280,845
265,266
265,266280,845231,165345,309596,12100
   > Total Current Liabilities 
488,062
807,088
560,809
309,737
162,357
236,470
216,148
216,148236,470162,357309,737560,809807,088488,062
       Short Long Term Debt 
0
0
91,368
86,910
92,221
147,397
150,534
150,534147,39792,22186,91091,36800
       Accounts payable 
358,647
663,683
426,373
127,962
31,477
71,788
52,722
52,72271,78831,477127,962426,373663,683358,647
       Other Current Liabilities 
12,665
12,993
12,861
94,865
33,952
10,572
951
95110,57233,95294,86512,86112,99312,665
   > Long-term Liabilities 
0
0
35,312
35,534
68,807
44,375
49,118
49,11844,37568,80735,53435,31200
       Long-term Liabilities Other 
0
0
5,413
1
0
-1
-1
-1-1015,41300
> Total Stockholder Equity
0
0
231,564
234,846
267,662
283,606
317,044
317,044283,606267,662234,846231,56400
   Retained Earnings 
75,713
78,955
83,026
86,308
119,125
135,068
143,991
143,991135,068119,12586,30883,02678,95575,713
   Accumulated Other Comprehensive Income 0000000
   Capital Surplus 0000000
   Treasury Stock0000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue520,806
Cost of Revenue-410,295
Gross Profit110,511110,511
 
Operating Income (+$)
Gross Profit110,511
Operating Expense-490,251
Operating Income30,555-379,740
 
Operating Expense (+$)
Research Development0
Selling General Administrative3,579
Selling And Marketing Expenses0
Operating Expense490,2513,579
 
Net Interest Income (+$)
Interest Income60
Interest Expense-17,283
Other Finance Cost-724
Net Interest Income-17,947
 
Pretax Income (+$)
Operating Income30,555
Net Interest Income-17,947
Other Non-Operating Income Expenses0
Income Before Tax (EBT)12,48930,555
EBIT - interestExpense = -17,283
9,855
27,138
Interest Expense17,283
Earnings Before Interest and Taxes (EBIT)029,772
Earnings Before Interest and Taxes (EBITDA)45,807
 
After tax Income (+$)
Income Before Tax12,489
Tax Provision-2,634
Net Income From Continuing Ops9,8559,855
Net Income9,855
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net017,947
 

Technical Analysis of Concord Drugs Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Concord Drugs Ltd. The general trend of Concord Drugs Ltd is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Concord Drugs Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Concord Drugs Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 38.30 < 39.05 < 40.95.

The bearish price targets are: 33.00 > 33.00 > 32.85.

Tweet this
Concord Drugs Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Concord Drugs Ltd. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Concord Drugs Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Concord Drugs Ltd. The current macd is -1.73394149.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Concord Drugs Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Concord Drugs Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Concord Drugs Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Concord Drugs Ltd Daily Moving Average Convergence/Divergence (MACD) ChartConcord Drugs Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Concord Drugs Ltd. The current adx is 32.64.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Concord Drugs Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Concord Drugs Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Concord Drugs Ltd. The current sar is 37.62.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Concord Drugs Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Concord Drugs Ltd. The current rsi is 39.74. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Concord Drugs Ltd Daily Relative Strength Index (RSI) ChartConcord Drugs Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Concord Drugs Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Concord Drugs Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Concord Drugs Ltd Daily Stochastic Oscillator ChartConcord Drugs Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Concord Drugs Ltd. The current cci is -96.74175894.

Concord Drugs Ltd Daily Commodity Channel Index (CCI) ChartConcord Drugs Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Concord Drugs Ltd. The current cmo is -16.25324221.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Concord Drugs Ltd Daily Chande Momentum Oscillator (CMO) ChartConcord Drugs Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Concord Drugs Ltd. The current willr is -67.69436997.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Concord Drugs Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Concord Drugs Ltd Daily Williams %R ChartConcord Drugs Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Concord Drugs Ltd.

Concord Drugs Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Concord Drugs Ltd. The current atr is 2.46540423.

Concord Drugs Ltd Daily Average True Range (ATR) ChartConcord Drugs Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Concord Drugs Ltd. The current obv is 1,518,724.

Concord Drugs Ltd Daily On-Balance Volume (OBV) ChartConcord Drugs Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Concord Drugs Ltd. The current mfi is 31.08.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Concord Drugs Ltd Daily Money Flow Index (MFI) ChartConcord Drugs Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Concord Drugs Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Concord Drugs Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Concord Drugs Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.742
Ma 20Greater thanMa 5037.500
Ma 50Greater thanMa 10040.822
Ma 100Greater thanMa 20040.797
OpenGreater thanClose34.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Concord Drugs Ltd with someone you think should read this too:
  • Are you bullish or bearish on Concord Drugs Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Concord Drugs Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Concord Drugs Ltd

I send you an email if I find something interesting about Concord Drugs Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Concord Drugs Ltd.

Receive notifications about Concord Drugs Ltd in your mailbox!